1. Heterologous Production of Bacteriocin EMM1 from Pseudomonas Protegens and its Antimicrobial Activity against Multidrug-resistant Clinical Isolates.
- Author
-
Bernabé-Pérez, Edith A., Gaytán, Paul, Juárez-González, Victor Rivelino, Hernández-García, Ismael J., Tapia-Pastrana, Gabriela, Quintero-Hernández, Verónica, and Martínez-Martínez, Lucía Lourdes
- Abstract
Background: Bacteria produce antimicrobial compounds to compete for nutrients and space in particular habitat. Bacteria of the genus Pseudomonas have gained relevance in recent years due to their ability to produce bacteriocins and a wide range of secondary metabolites of medical and agricultural importance, such as 2,4-diacetylphloroglucinol (DAPG), ribosomal peptide synthetase (RPS), pyrrolnitrin (PRN) and pyoluteorin (PLT), which have exhibited antimicrobial properties. Objective: The present research focused on establishing an expression system for the heterologous production of the bacteriocin EMM1 from Pseudomonas protegens in a soluble, stable and biologically active form in order to evaluate the performance of this protein in the treatment of emerging drug-resistant bacteria of clinical interest. Methodology: The 840 bp bacteriocin EMM1 gene was obtained from Pseudomonas protegens strain, cloned into the expression vector pET28b(+) and subsequently expressed in Escherichia coli Gold BL21 (DE3). The amino acid tag MASKEEDN (PFT) was added at the N-terminal end of the bacteriocin to improve its solubility and stability in order to achieve its purification by immobilized metal affinity chromatography (IMAC). The antimicrobial activity was evaluated by inhibition zones and plate microdilution on reference and clinical strains and the hemolytic activity on human blood cells was determined. Results: This recombinant protein named EMM1-PFT showed unique characteristics with respect to its size, stability and oligomeric state. Bactericidal activity was observed on reference strains E. coli ATCC 3922, E. coli ATCC 25922, Staphylococcus aureus ATCC 25923, clinical isolates of Pseudomonas aeruginosa and Yersinia enterocolitica and low hemolytic activity on human erythrocytes. Conclusions: A new recombinant protein was obtained that was partially characterized and active against clinical strains. These advances allow us to suggest further studies to understand its mechanism of action, synergistic activity with antibiotics and improvement of the spectrum of antibacterial activity through protein engineering. EMM1-PFT is a new alternative for the eradication of emerging MDR bacteria. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF